PTEN and melanoma: This transgenic melanoma mouse model was originally developed to harness two significant oncogenic alterations [BRAFV600E and PTEN (loss)], but it is not representative of the larger patient population since in our analysis of the Cutaneous Melanoma TCGA PanCancer data, we found that only 5.0% of cases had co‐occurrence of both mutations (Fig. S1A).